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G protein-coupled receptors (GPCRs) are a large su-perfamily of plasmamembrane receptors, which me-
diate a number of physiological regulatory mechanisms.
They are also major drug targets used for a variety of
diseases. Of particular importance to the field of endocri-
nology, GPCRs have recognized roles in the physiology,
pathophysiology, and therapy of diabetes mellitus and
metabolic syndrome. A GPCR forum held at ENDO2013
chaired by Agnes Schonbrunn, Deborah L. Segaloff, and
Robert Peter Millar addressed this topic under the title,
New light on GPCRs in the pathophysiology of diabetes
and metabolic disorders. In this special issue, the editors
of Molecular Endocrinology invited the speakers of this
event to present their views and most recent results in this
field.
Human pancreatic islets of Langerhans express a large
number of GPCRs. Most of these receptors are present in
insulin-producing-cells, which is themain population of
human islet cells. In these cells, as well as in other islet
cells, GPCRs mediate sympathetic and parasympathetic
actions and the effects of incretins, such as glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic
peptide. However, the physiological and therapeutic rel-
evance of the many GPCRs expressed in pancreatic islets
are still unknown. GLP-1 mimetics are used successfully
in the treatment of type 2 diabetes mellitus (T2DM), dem-
onstrating the relevance of targeting specific GPCRs to
the treatment of this disease. Therefore, GPCRs become a
major target of drug development for antidiabetic therapy
because they can increase insulin secretion, potentiate the
effects of glucose, and increase -cell mass by stimulating
cell proliferation or decreasing apoptosis.
GLP-1 receptors are important targets for the therapy
of T2DM. Patrick Sexton and colleagues describe the di-
vergent effects of the responses of endogenous and exog-
enous GLP-1 receptor ligands on the function of the re-
ceptor. Their work suggests that naturally occurring
polymorphisms of this receptor have the potential to pro-
duce differential responses to distinct GLP-1 receptor li-
gands. Furthermore, these findings reveal the importance
of individualized therapy, which takes these variations
into consideration.
Receptors for free fatty acids (FFAs) are either vali-
dated (FFA1) or potential (FFA2-FFA4) therapeutic tar-
gets for the treatment of T2DM and other diseases. Con-
sistently, FFA1 receptors are highly expressed in
pancreatic islets, whereas other FFA receptors are also
expressed in this tissue. GraemeMilligan and his cowork-
ers present data about the limitations of rodent models to
study the human relevance of FFA receptors and demon-
strate that their polymorphisms can have functional con-
sequences. M3 muscarinic receptors are the major medi-
ators of the effects of acetylcholine released during
parasympathetic receptor on insulin and glucagon
secretions.
Jürgen Wess and colleagues present their findings,
which demonstrated physiological roles of M3 receptors
in rodent models and present an innovative approach us-
ing an M3 receptor-based designer receptor, which en-
abled them to chronically activate in -cells a Gq-coupled
receptor by an otherwise pharmacologically inert drug.
Their data show that chronic stimulation of this pathway
protected mice against experimentally induced diabetes
and glucose intolerance.
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Ralph Jockers and his colleagues highlight the emerg-
ing relationship between defects in melatonin signaling/
circadian rhythms and metabolic diseases, including
T2DM. They use large-scale exon sequencing and show
that functional and genetic associations between defective
melatonin MT2 receptor signaling and T2DM risk pro-
vides a solid basis for the relationship between melatonin
and T2DM in humans. They conclude that in the future
defining the functional defects in carriers of rare MT2
receptor mutations can help to provide personalized ther-
apies for these patients.
Ustione and his colleagues review the negative feed-
back role of dopamine in the regulation of insulin secre-
tion. They report that L-DOPA, coming from the gut after
ameal, can be converted to dopamine in-cells and exerts
an opposite effect on insulin secretion than incretins. This
makes it a candidate antiincretin signal, which can con-
tribute to the positive effects of bariatric surgery on
hyperglycemia.
Finally, Melanie Cobb and her coworkers highlight
how the T1 receptor, a class C GPCR originally thought
to be restricted to taste perception in gustatory neurons,
can sense nutrients in many different tissues. Their data
suggest that T1 receptor and other class C GPCRs have
wider physiological roles than originally thought and
present findings suggesting their possible function in met-
abolic regulation.
The papers presented in this special issue demonstrate
the importance of targeting GPCRs for the treatment of
other metabolic diseases, including T2DM.
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